Source: FDA, National Drug Code (US) Revision Year: 2024
LetibotulinumtoxinA-wlbg is an acetylcholine release inhibitor and a neuromuscular blocking agent. LetibotulinumtoxinA-wlbg is a 900 kDa botulinum toxin typeA, produced from fermentation of Clostridium botulinum.
LETYBO (letibotulinumtoxinA-wlbg) for injection is supplied as a sterile, preservative-free, white, freeze-dried powder in a single-dose vial for intramuscular use after reconstitution. Each vial contains either 50 Units of letibotulinumtoxinA-wlbg, albumin human (0.25 mg) and sodium chloride (0.45 mg); or 100 Units of letibotulinumtoxinA-wlbg, albumin human (0.5 mg) and sodium chloride (0.9 mg).
| Dosage Forms and Strengths |
|---|
|
For injection: 50 Units or 100 Units of white, freeze-dried powder in a single-dose vial for reconstitution with sterile, preservative-free 0.9% Sodium Chloride Injection, USP. |
| Drug | Countries | |
|---|---|---|
| LETYBO | Austria, Canada, Cyprus, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Malta, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
